Dominik Honold

Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2

Sarah Schemmert, Elena Schartmann, Dominik Honold et al. · Neurobiology of Disease · 2018 · 16 citations · Full text

In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer’s Disease

Sarah Schemmert, Luana Cristina Camargo, Dominik Honold et al. · International Journal of Molecular Sciences · 2021 · 14 citations · Full text

Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice

Tina Dunkelmann, Sarah Schemmert, Dominik Honold et al. · Journal of Alzheimer s Disease · 2018 · 12 citations · Full text

Homozygous Tba2.1 Mice, Neurochemical Biomarkers, Comprehensive Characterization +24

Development of an α-synuclein fibril and oligomer specific tracer for diagnosis of Parkinson's disease, dementia with Lewy bodies and multiple system atrophy

Marc Sevenich, Dominik Honold, Antje Willuweit et al. · Neurochemistry International · 2022 · 12 citations

Multiple System Atrophy, Pathology, Neurochemical Biomarkers +16

In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer’s Disease

Elena Schartmann, Sarah Schemmert, Nicole Niemietz et al. · Journal of Alzheimer s Disease · 2018 · 11 citations · Full text